Methylation-associated silencing of the Thrombospondin-1 gene in human neuroblastoma

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6299-6310

  Yang, Qi Wei ^a   Liu, Shuqing ^a   Tian, Yufeng ^a   Salwen, Helen R ^a   Chlenski, Alexandre ^a   Weinstein, Joanna ^a   Cohn, Susan L ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; LIPOCORTIN 5; LUCIFERASE; MESSENGER RNA; THROMBOSPONDIN 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; FEMALE; FLUORESCENCE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROBLASTOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; TUMOR XENOGRAFT;

ANIMALS; AZACITIDINE; CELL DIVISION; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; PROMOTER REGIONS (GENETICS); THROMBOSPONDIN 1; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 0141885092     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Brodeur, G. M., and Maris, J. M. Neuroblastoma. In: P. A. Pizzo and D. G. Poplack (eds.), Principles and Practice of Pediatric Oncology, 4 ed., pp. 895-937. Philadelphia: Lippincott-Raven, 2001.
2. Brodeur, G. M., Pritchard, J., Berlhold, F., Carlsen, N. L., Castle, V., Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., Hedborg. F., Kaneko, M., Kemshead, J., Lampert, F., Lee, R. E. J., Look, A. T., Pearson, A. D. J., Philip, T., Roald, B., Sawada, T., Seeger, R. C., Tsuchida. Y., and Voute, P. A. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol., 11: 1466-1477, 1993.
3. Maris, J. M., and Matthay, K. K. Molecular biology of neuroblastoma. J. Clin. Oncol., 17: 2226-2279, 1999.
4. Meitar, D., Crawford, S. E., Rademaker, A. W., and Cohn, S. L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neurolastoma. J. Clin. Oncol., 14: 405-414, 1996.
5. Eggert, A., Ikegaki, N., Kwiatkowski, J., Zhao, H., Brodeur, G. M., and Himelstein, B. P. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res., 6: 1900-1908, 2000.
6. 5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res., 60: 712-721, 2000.
7. Ribatti, D., Surico, G., Vacca, A., De Leonardis, F., Lastilla, G., Montaldo, P. G., Rigillo, N., and Ponzoni, M. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci., 68: 1161-1168, 2001.
8. Huang, D., Rutkowski, J. L., Brodeur, G. M., Chou, P. M., Kwiatkowski, J. L., Babbo, A., and Cohn, S. L. Schwann cell-conditioned medium inhibits angiogenesis. Cancer Res., 60: 5966-5971, 2000.
9. Chlenski, A., Liu, S., Crawford, S. E., Volpert, O. V., DeVries, G. H., Evangelista, A., Yang, Q., Salwen, H. R., Farrer, R., Bray, J., and Cohn, S. L. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res., 62: 7357-7363, 2002.
10. Crawford, S. E., Stellmach, V., Ranalli, M., Huang, X., Huang, L., Volpert, O., De Vries, G. H., Abramson, L. P., and Bouck, N. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J. Cell Sci., 114: 4421-4428, 2001.
11. Briet, S., Ashman, K., Wilting, J., Rossler, J., Hatzi, E., Fotsis, T., and Schweigerer, L. The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as Activin A. Cancer Res., 60: 4596-4601, 2000.
12. Hatzi, E., Murphy, C., Zoephel, A., Rasmussen, H., Morbidelli, L., Ahorn, H., Kunisada, K., Tontseh, U., Klenk, M., Yamauchi-Takihara, K., Ziche, M., Rofstad, E. K., Schweigerer, L., and Fotsis, T. N-mye oncogene overerexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses nueroblastoma tumor growth. Oncogene, 21: 3552-3561, 2002.
13. Eggert, A., Grotzer, M. A., Ikegaki, N., Liu, X. G., Evans, A. E., and Brodeur, G. M. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res., 62: 1802-1808, 2002.
14. Davidoff, A. M., Leary, M. A., Ng, C. Y., and Vanin, E. F. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J. Pediatr. Surg., 36; 30-36, 2001.
15. Katzenstein, H. M., Rademaker, A. W., Senger, C., Salwen, H., Nguyen, N., and Cohn, S. L. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin. Cancer Res., 5: 4273-4278, 1999.
16. Nagabuchi, E., VanderKolk, W. E., Une, Y., and Ziegler, M. M. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J. Pediatr. Surg., 32: 287-293, 1997.
17. Wassberg, E., Pahlman, S., Westlin, J. E., and Christofferson, R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr. Res., 41: 327-333, 1997.
18. Shusterman, S., Grupp, S. A., Barr, R., Carpentieri, D., Zhao, H., and Maris, J. M. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin. Cancer Res., 7: 977-984, 2001.
19. Bornstein, P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol., 130: 503-506, 1995.
20. Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., and Bouck, N. P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA, 87: 6624-6628, 1990.
21. Jimenez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., and Bouck, N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med., 6: 41-48, 2000.
22. Tolsma, S. S., Volpert, O. V., Good, D. J., Frazier, W. A., Polverini, P. J., and Bouck, N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol., 122: 497-511, 1993.
23. Mettouchi, A., Cabon, F., Montreau, N., Vernier, P., Mercier, G., Blangy, D., Tricoire, H., Vigier, P., and Binetruy, B. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J., 13: 5668-5678, 1994.
24. Sheibani, N., and Frazier, W. A. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. Cancer Lett., 107: 45-52, 1996.
25. Sheibani, N., and Frazier, W. A. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc. Natl. Acad. Sci. USA, 92: 6788-6792, 1995.
26. Weinstat-Saslow, D. L., Zabrenetzky, V. S., VanHoutte, K., Frazier, W. A., Roberts, D. D., and Steeg, P. S. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res., 54: 6504-6511, 1994.
27. Grossfeld, G. D., Ginsberg, D. A., Stein, J. P., Bochner, B. H., Esrig, D., Groshen, S., Dunn, M., Nichols, P. W., Taylor, C. R., Skinner, D. G., and Cote, R. J. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl. Cancer Inst., 89: 219-227, 1997.
28. Zabrenetzky, V., Harris, C. C., Steeg, P. S., and Roberts, D. D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer, 59: 191-195, 1994.
29. Yamashita, Y., Kurohiji, T., Tuszynski, G. P., Sakai, T., and Shirakusa, T. Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer (Phila.), 82: 632-638, 1998.
30. Laherty, C. D., Gierman, T. M., and Dixit, V. M. Characterization of the promoter region of the human thrombospondin gene. DNA sequences within the first intron increase transcription. J. Biol. Chem., 264: 11222-11227, 1989.
31. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Wash. DC), 265: 1582-1584, 1994.
32. Li, Q., Ahuja, N., Burger, P. C., and Issa, J. P. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene, 18: 3284-3289, 1999.
33. Laird, P. W., and Jaenisch, R. DNA methylation and cancer. Hum. Mol. Genet., 3: 1487-1495, 1994.
34. Nan, X., Ng, H. H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., and Bird, A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (Lond.), 393: 386-389, 1998.
35. Jones, P. L., Veenstra, G. J., Wade, P. A., Vermaak, D., Kass, S. U., Landsberger, N., Strouboulis, J., and Wolffe, A. P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet., 19: 187-191, 1998.
36. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., and Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet., 21: 103-107, 1999.
37. Foley, J., Cohn, S. L., Salwen, H. R., Chagnovich, D., Cowan, J., Mason, K. L., and Parysek, L. M. Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line. Cancer Res., 51: 6338-6345, 1991.
38. Cohn, S. L., Salwen, H., Quasney, M. W., Ikegaki, N., Cowan, J. M., Herst, C. V., Kennett, R. H., Rosen, S. T., DiGiuseppe, J. A., and Brodeur, G. M. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification. Oncogene, 5: 1821-1827, 1990.
39. Ciccarone, V., Spengler, B. A., Meyers, M. B., Biedler, J. L., and Ross, R. A. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res., 49: 219-225, 1989.
40. Reynolds, C. P., Tomayko, M. M., Donner, L., Helson, L., Seeger, R. C., Triche, T. J., and Brodeur, G. M. Biological classification of cell lines derived from human extra-cranial neural tumors. Prog. Clin. Biol. Res., 271: 291-306, 1988.
41. Manohar, C. F., Short, M. L., Nguyen, A., Nguyen, N. N., Chagnovich, D., Yang, Q., and Cohn, S. L. HuD, a neuronal-specific RNA-binding protein, increases the in vivo stability of MYCN RNA. J. Biol. Chem., 277: 1967-1973, 2002.
42. Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J., Joshi, V. V., and Roald, B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer (Phila.), 86: 349-362, 1999.
43. Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods, 184: 39-51, 1995.
44. Chen, S. Y., Yang, A. G., Chen, J. D., Kute, T., King, C. R., Collier, J., Cong, Y., Yao, C., and Huang, X. F. Potent antitumour activity of a new class of tumour-specific killer cells. Nature (Lond.), 385: 78-80, 1997.
45. Thiele, C. J., Reynolds, C. P., and Israel, M. A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature (Lond.), 313: 404-406, 1985.
46. Schubert, D., and Jacob, F. 5-Bromodeoxyuridine-induced differentiation of a neuroblastoma. Proc. Natl. Acad. Sci. USA, 67: 247-254, 1970.
47. Reynolds, C. P., and Maples, J. Modulation of cell surface antigens accompanies morphological differentiation of human neuroblastoma cell lines. Prog. Clin. Biol. Res., 175: 13-37, 1985.
48. Sidell, N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J. Natl. Cancer Inst., 68: 589-596, 1982.
49. Roberts, D. D. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J., 10: 1183-1191, 1996.
50. Yan, P., Muhlethaler, A., Bourloud, K. B., Beck, M. N., and Gross, N. Hypermethylation-mediated regulation of CD44 gene expression in human neuroblastoma. Genes Chromosomes Cancer, 36: 129-138, 2003.
51. Harada, K., Toyooka, S., Maitra, A., Maruyama, R., Toyooka, K. O., Timmons, C. F., Tomlinson, G. E., Mastrangelo, D., Hay, R. J., Minna, J. D., and Gazdar, A. F. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene, 21: 4345-4349, 2002.
52. Astuti, D., Agathanggelou, A., Honorio, S., Dallol, A., Martinsson, T., Kogner, P., Cummins, C., Neumann, H. P., Voutilainen, R., Dahia, P., Eng, C., Maher, E. R., and Latif, F. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene, 20: 7573-7577, 2001.
53. Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., and Kidd, V. J. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med., 6: 529-535, 2000.
54. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
55. Herman, J. G., Jen, J., Merlo, A., and Baylin, S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res., 56: 722-727, 1996.